nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.09.2013 | Original Paper

The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma

verfasst von: Eleonora Brunello, Giuseppe Bogina, Emilio Bria, Marco Vergine, Giuseppe Zamboni, Serena Pedron, Isabella Daniele, Jenny Furlanetto, Luisa Carbognin, Marcella Marconi, Erminia Manfrin, Merdol Ibrahim, Keith Miller, Giampaolo Tortora, Annamaria Molino, Bharat Jasani, Serena Beccari, Franco Bonetti, Marco Chilosi, Guido Martignoni, Matteo Brunelli

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple (ER-, PR-, HER2-) negative breast carcinoma lack targeted therapies, making this group of tumors difficult to treat. By definition, the lack of HER2 expression means a case scoring 0 or 1+ after immunophenotypical analysis and makes the patients avoiding therapeutical chances with anti-HER2 inhibitors. We sought to recruit from a group of triple negative breast carcinoma, patients eligible for effective personalized targeted therapy with anti-HER therapies on the basis of their HER2 gene status.

Methods

135 patients diagnosed with IHC triple negative breast carcinoma were studied. Whole tissue sections were used for in situ hybridization analysis.

Results

8/100 (8 %) of ductal-type triple negative breast carcinoma presented Her-2/neu gene amplification versus 2/35 (5.7 %) non-ductal triple negative breast carcinoma. Three cases showed a ratio 2.5. One case showed Her-2/neu heterogeneous gene amplification, ratio 2.3. The other six showed from 7 to 8 absolute Her-2/neu gene copy number. Two cases staged pT1c, and eight cases staged pT2. Eight cases graded G3 and two cases G2.

Conclusion

(1) Eight percentage of ductal and 5.7 % non-ductal-type triple negative breast carcinoma present Her-2/neu gene amplification, (2) the standard diagnostic flowchart “do not FISH in 0–1+ (HER2-) breast carcinoma” should be replaced by “do FISH in triple (ER-, PR-, HER2-) negative breast carcinoma,” to avoid loss of therapeutical chances in a cohort of such a patients, (3) we demonstrated the identification of a small but significant subset of patients targetable with anti-HER2 inhibitors, giving patients affected by (ex)triple negative breast carcinoma new personalized therapeutical chances.

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T et al (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24:157–167PubMedCrossRef

Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I et al (2009) External quality assurance of HER2 FISH and ISH testing: 3 years of the UK national external quality assurance scheme. Am J Clin Pathol 131:106–111PubMedCrossRef

Bartlett JM, Starczynski J, Atkey N, Kay E, O’Grady A et al (2011) HER2 testing in the UK: recommendations for breast and gastric in situ hybridisation methods. J Clin Pathol 64:649–653PubMedCrossRef

Bloom KJ, Cote RJ (2011) Counterpoint: both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation. Clin Chem 57:983–985PubMedCrossRef

Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A et al (2008) HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol 129:907–911PubMedCrossRef

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ et al (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30:2615–2623PubMedCrossRef

Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244PubMedCrossRef

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648PubMed

Crown J, O’Shaughnessy J, Gullo G (2012) Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 23(Suppl 6):vi56–vi65PubMedCrossRef

Dendukuri N, Khetani K, McIsaac M, Brophy J (2007) Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 176:1429–1434PubMed

Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M et al (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199:418–423PubMedCrossRef

Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U et al (2009) Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 27:2962–2969PubMedCrossRef

Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938–1948PubMedCrossRef

Iorfida M, Dellapasqua S, Bagnardi V, Cardillo A, Rotmensz N et al (2012) HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH? Ann Oncol 23:1371–1372PubMedCrossRef

Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409–1411PubMedCrossRef

Pauletti G, Dandekar S, Rong H, Ramos L, Peng H et al (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651–3664PubMed

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S et al (2007) A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol 15:94–102PubMedCrossRef

Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52:108–118PubMedCrossRef

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef

Starczynski J, Atkey N, Connelly Y, O’Grady T, Campbell FM et al (2012) HER2 gene amplification in breast cancer: a rogues’ gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol 137:595–605PubMedCrossRef

Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z (2011) Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117:48–53PubMedCrossRef

Walker RA, Bartlett JM, Dowsett M, Ellis IO, Hanby AM et al (2008) HER2 testing in the UK: further update to recommendations. J Clin Pathol 61:818–824PubMedCrossRef

Titel: The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma
verfasst von: Eleonora Brunello
Giuseppe Bogina
Emilio Bria
Marco Vergine
Giuseppe Zamboni
Serena Pedron
Isabella Daniele
Jenny Furlanetto
Luisa Carbognin
Marcella Marconi
Erminia Manfrin
Merdol Ibrahim
Keith Miller
Giampaolo Tortora
Annamaria Molino
Bharat Jasani
Serena Beccari
Franco Bonetti
Marco Chilosi
Guido Martignoni
Matteo Brunelli
Publikationsdatum: 01.09.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1479-0

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma